This article was downloaded by: [University of Chicago Library] On: 18 November 2014, At: 04:02 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

Phosphonates Derivatives of 2',3'-Dideoxy-2',3'-didehydro-pentopyranosyl Nucleosides

María-Jesús Péarez-Péarez ^a , Bogdan Doboszewski ^a , Erik De Clercq ^b & P. Herdewijn ^a

^a Medicinal Chemistry

^b Experimental Chemotherapy, Rega Institute, Minderbroedersstraat
10, B-3000, Leuven, Belgium
Published online: 16 Feb 2007.

To cite this article: María-Jesús Péarez-Péarez , Bogdan Doboszewski , Erik De Clercq & P. Herdewijn (1995) Phosphonates Derivatives of 2',3'-Dideoxy-2',3'-didehydro-pentopyranosyl Nucleosides, Nucleosides and Nucleotides, 14:3-5, 707-710

To link to this article: <u>http://dx.doi.org/10.1080/15257779508012454</u>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions

PHOSPHONATES DERIVATIVES OF 2',3'-DIDEOXY-2',3'-DIDEHYDRO-PENTOPYRANOSYL NUCLEOSIDES

María-Jesús Pérez-Pérez, Bogdan Doboszewski, Erik De Clercq[#] and Piet Herdewijn^{*} Medicinal Chemistry and [#]Experimental Chemotherapy, Rega Institute, Minderbroedersstraat 10, B-3000 Leuven, Belgium

Abstract: Adenine and thymine derivatives of 2',3'-dideoxy-2',3'-didehydropento-pyranosyl nucleosides carrying a phosphonomethyl moiety at their 4'-O-position and in a *cis* relationship with the heterocyclic base have been synthesized.

Since the discovery of the potent anti-HIV activity of AZT, ddI and d4T, 2',3'dideoxy- and 2',3'-dideoxy-2',3'-didehydropentofuranosyl nucleosides have been extensively studied as potential antivirals¹. However, saturated and unsaturated di- and trideoxypyranosyl nucleosides have received little attention²⁻⁷. The absence of antiviral activity for most of the nucleoside analogues with a six membered ring carbohydrate moiety has been related to their poor recognizition by cellular kinases, and, hence, to the lack of the formation of their triphophates, the active metabolite interacting with the reverse transcriptase of HIV. In this activation process, the generation of the monophosphate is, in most of the cases, the limiting step. One extensively used and successful strategy to overcome this first phosphorylation is the preparation of nucleoside phosphonates. It has already been shown^{8,9} that, in this respect, a phosphonomethoxy and a methylphosphate moiety act as isosteric and isoelectronic functions.

As part of our programme on the synthesis of six-membered ring nucleosides, we have now synthesized pentopyranosyl nucleosides of formula 1, and, in the case of the adenine congener, its enantiomer 2, where the heterocyclic base and the phosphonomethoxy moiety are in a 1,4-*cis* relationship. These compounds could be considered as ring-enlarged analogues of d4T-MP and d4A-MP, respectively, carrying a phophonomethoxy moiety as isoster of the monophosphate function. The 1,4-*cis* configuration between the base and the OH to be phosphorylated is also present in 1,5-anhydrohexitol nucleosides that have been synthesized by our group, and that show antiviral activity¹⁰.



For the synthesis of the thymine derivative 1a, a stereospecific pathway was devised starting from peracetylated D-xylose (scheme 1). Reaction of this (3) with silvlated thymine in the presence of trimethylsilyl triflate afforded the β -D-pyranosylnucleoside (4), which was deacetylated by reaction with NaOMe/MeOH (5, 60% from 3). Then, the 4'-OH of the xylose moiety was selectively protected by treatment with Bu₂SnO in methanol and reaction with 1.1 eq. of benzoyl chloride in dioxane/DMF (4:1) (6, 79% yield). The olefin 7 was obtained from the diol 6 by reaction with chlorodiphenylphosphine/iodine/imidazole (2.2:2.2:4eq./diol) in toluene/acetonitrile and treatment with Zn^{11} to complete the transformation of the intermediate iodo diphenylphosphinate to the unsaturated compound. The benzoyl group was then removed by treatment with methanolic ammonia (65% of 8 from 6). In the next step, the configuration of the stereogenic centre at the 4'-position was inverted using benzoic acid under Mitsunobu conditions¹². After deprotection, the L-nucleoside **10** was obtained in 75% yield. No allylic rearrangement was detected. The phosphonomethyl moiety was introduced by reaction of 10 with NaH and diisopropyl[(p-tolylsulfonyl)oxy] methanephosphonate^{13,14} in DMF at 40°C. The 4'-O-alkylated derivative 11 was deprotected by treatment with trimethylsilyl bromide and hydrolysis, to afford, after purification, the disodium salt of 1a.

A different reaction sequence was followed for the synthesis of the adenine derivatives. Our earlier investigations have shown that 2',3'-unsaturated nucleosides can be obtained by direct condensation of di-O-acylated-D-xylal with heterocyclic bases in boiling DMF, without external acid catalysis¹⁵. Following this procedure (Scheme 2), the N-9 adenine derivatives **13** and **14** were obtained by reaction of di-p-NO₂-benzoyl-D-xylal with N⁶-benzoyladenine. The mixture of anomers was resolved after selective deprotection of the alcohol moiety with NaOMe in MeOH:dioxane, yielding the α -D- and β -D-glycero-pent-2'-enosyl nucleosides **16** and **15** in 19% and 25% yield, respectively, from the xylal. The stereochemical assignment of both isomers was determined by X-Ray crystallography¹⁵. It should be mentioned that no appreciable amounts of 3'-substituted-1',2'-unsaturated nucleosides were detected.

The configuration of the 4'-OH center in the β -anomer 15 was inverted by reaction with *p*-nitrobenzoic acid under Mitsunobu conditions and selective deprotection, to yield



Scheme 1



the 1,4-*cis*-substituted olefin **18** in 73% yield. Again, no allylic rearrangement was detected. Reaction of the alcohols **16** and **18** with NaH and diisopropyl [(p-tolylsulfonyl)-oxy]methanephosphonate afforded the 4'-O-alkylated derivatives which were deprotected by successive treatment with methanolic ammonia and trimethylsilyl bromide in DMF. The phosphonates derivatives were isolated as their ammonium salts **2** and **1b** (30% and 24% yield, from their respective allylic alcohols **16** and **18**). The treatment with TMSiBr had to be carried out in the presence of an excess of 2,6-lutidine¹⁶, otherwise extensive decomposition was observed. This seems to indicate the sensitivity of the glycosidic bond in these structures to acidic conditions, and contrasts with the greater stability reported for the furanose analogue⁹.

When tested for inhibitory activity against virus replication in cell culture including HIV-1, HIV-2, HSV-1, HSV-2, VZV and HCMV, the phosphonate derivatives 1 and 2 were found to be inactive at concentrations up to 100 μ g/ml. Also no toxicity to the cell monolayers was observed.

ACKNOWLEDGEMENTS

M.J. Pérez-Pérez is grateful to the Fundación Ramón Areces (Spain) for a postdoctoral scholarship. B. Doboszewski is a research fellow of the "Onderzoeksfonds K.U. Leuven". We also wish to thank Prof. J. Balzarini, Dr. R. Snoeck, Dr. G. Andrei, Mrs. A. Absillis, Mrs. A. Van Lierde, Mrs. F. De Meyer and Mrs. A. Camps for help with the antiviral evaluations.

REFERENCES

- 1. Herdewijn, P.; Balzarini, J.; De Clercq, E.; Advances in Antiviral Drug Design. JAI Press. 1993.Vol. 1, pp 233-318.
- a) Herdewijn, P.; Van Aerschot, A. Bull. Soc. Chim. Belg. 1990, 99, 895. b) Herdewijn, P.; Van Aerschot, A.; Balzarini, J.; De Clercq, E. Nucleosides & Nucleotides, 1991, 10, 119.
- 3. Hanssen, H; Pedersen, E. Arch. Pharm.(Weinheim), 1992, 325, 491.
- 4. Bessodes, M.; Egron, M.J.; Filippi, J.; Antonakis, K. J. Chem. Soc. Perkin Trans. I, 1990, 3035.
- 5. Björsne, M.; Classon, B.; Kvarnstöm, I.; Samuelsson, B. Tetrahedron, 1993, 49, 8637.
- 6. Augustyns, K.; Rozenski, J.; Van Aerschot, A.; Janssen, G.; Herdewijn, P. J. Org. Chem., 1993, 58, 2977.
- 7. Sztaricskai, F; Dinya, Z.; Batta, G.; Gergely, L.;Szabo, B. Nucleosides & Nucleotides, 1992, 11, 11.
- 8. De Clercq, E.; Holy, A.; Rosenberg, I.; Sakuma, T.; Balzarini, J.; Maudgal, P.C. Nature, 1986, 323,464.
- 9. Kim, C.U.; Luh, B.Y.; Martin, J.C. J. Org. Chem., 1991, 56, 2642
- 10. Verheggen, I.; Van Aerschot, A.; Toppet, S.; Snoeck, R.; Janssen, G.; Claes, P.; Balzarini, J.; De Clercq, E.; Herdewijn, P. J. Med. Chem., 1993, 36, 2033.
- 11. Liu, Z.; Classon, B.; Samuelson, B. J. Org. Chem., 1990, 55, 4273.
- 12. For a recent review, see: Hughes, D.L., in *Organic Reactions*. Paquette, L.A., (Ed.); John Wiley and Sons, New York, **1992**, *42*, 344.
- 13. Holy, A.; Rosenberg, I. Collect Czech Chem. Commun., 1982, 47, 3447.
- 14. Phillion, D.P.; Andrew, S.S. Tetrahedron Lett., 1986, 27, 1477.
- 15. See contribution to this issue by Doboszewski et al.
- This strategy has also been followed in the deprotection of other phosphonates sensitive to the release of hydrogen bromide under treatment with TMSiBr. See: a) Yu, K.L.; Bronson, J.J. et al, J. Med. Chem., 1992, 35, 2958; b) Kim, C.U.; Luh, B.Y.; Martin, J.C., Bioorg. Med. Chem. Lett. 1992, 2, 307.